SUVN-L1305022 demonstrates antipsychotic activity in vivo

Nov. 25, 2022

Researchers from Suven Life Sciences Ltd. presented the discovery and preclinical characterization of a novel muscarinic acetylcholine M4 receptor positive allosteric modulator (PAM), SUVN-L1305022.

BioWorld Science Conferences New compound Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for Nov. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 11, 2025.

UK launches strategy to replace animals in research as scientists voice concern

BioWorld

The U.K. government has published a road map for phasing out animal testing in life sciences research and announced £75 million (US$98.6 million) for work to...

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

Up the bladder ladder, Engene tweak means phase II bell rung

BioWorld

Engene Holdings Inc.’s protocol amendment to its phase II trial with detalimogene voraplasmid in bladder cancer worked out in a big way, and shares of the firm...